Washington, DC (UroToday.com) Seth Lerner, MD, FACS, from the Baylor College of Medicine in Houston, TX discussed FDA approval of therapies in the context of BCG shortages and alternative therapies. Definitions are important particularly with well-defined endpoints and disease states. Dr. Lerner discussed ongoing clinical trials including the SWOG 1602 (Prime) trial comparing strains of […]
Washington, DC (UroToday.com) During the John Quale Award Presentation, Amy Lim from MD Anderson, presented her research regarding the diagnostic approach in clinically node positive bladder cancer. Patients with modal metastatic bladder cancer are at a significantly increased risk of mortality. They performed a retrospective cohort study between 2006-2017 in patients with cTanyN1-3M0 disease. A total […]
Washington, DC (UroToday.com) Andrea Apolo, MD, from the National Institute of Health (NIH) in Bethesda, MD discussed adjuvant trials in muscle-invasive bladder cancer including Food and Drug Administration collaboration in trial design and endpoints. Multiple stakeholders including patient advocates were involved in a recent workshop with the FDA to improve trial design and drug approval. […]
Washington, DC (UroToday.com) Lee Hugar from the University of Pittsburgh presented his work regarding palliative care and bladder cancer. They found approximately 3.6% use of palliative care using SEER-Medicare data. Of 2185 patients with advanced bladder cancer (T4, N+ or M+), only 90 (4.1%) received palliative care. Predictors for use of palliative care include being […]
Washington, DC (UroToday.com) Jamie Marko from the NIH Clinical Center, Bethesda, MD discussed radiographic consideration prior to clinical trial enrollment. All pre-trial enrollment imaging for bladder cancer should be <4 wks prior to enrollment. Generally, >1cm cut-off for defining malignancy accepted. Always archive prior exams to refer if needed for unequivocal lesions. Defining progression should […]
Washington, DC (UroToday.com) Mary Dunn from the University of North Carolina discussed the introduction of palliative care in bladder cancer. Palliative care provided by a specially trained team, is appropriate at any stage of serious illness yet underutilized. This session was engaging and interactive which included presentations by both palliative care and bladder cancer experts […]
Washington, DC (UroToday.com) Gary Winzelberg, Associate Director of the University of North Carolina Palliative Care Program, discussed how urology can improve implementation and dissemination of palliative care. There are tremendous advances in cancer care that also bring challenges including prognostications with expanding treatment options, cancer pain management in the opioid epidemic, goal discordant concerns, financial […]
Prostate cancer is a disease that universally responds to androgen deprivation therapy (ADT), as it is driven by androgens and their interaction with androgen receptors (AR). However, over time, prostate cancer will become resistant to ADT, delineating the castration-resistant disease state. The field has adapted to address this problem with even more potent hormonal therapies […]
Hypofractionated bladder RT with or without image guided adaptive planning (HYBRID) is a multicentre clinical trial investigating “Plan of the Day” (PoD) adaptive radiotherapy for bladder cancer. To ensure correct PoD selection a pre-accrual guidance and assessment module was developed as part of an image guided radiotherapy quality assurance (IGRT QA) credentialing programme. This study […]
Although prostate cancer control using radiotherapy is dose-dependent, dose-volume effects on late toxicities in organs at risk, such as the rectum and bladder, have been observed. Both protons and carbon ions offer advantageous physical properties for radiotherapy, and create favorable dose distributions using fewer portals compared with photon-based radiotherapy. Thus, particle beam therapy using protons […]
